Since the beginning of last year, 34 lawmakers have each received more than $100,000 from pharmaceutical companies. Two of those — Reps. Greg Walden of Oregon, a key Republican committee chairman, and Kevin McCarthy of California, the House Republican majority leader — each received more […]
That stance, however, was at odds with its financial support of another group, the American Action Network, which was heavily involved in that effort to put an end to the ACA, often referred to as Obamacare, spending an estimated $10 million on an ad campaign […]
Promises by the pharmaceutical industry to contain prices are a familiar — and fleeting — phenomenon, say analysts who have watched the unstoppable rise in drug costs over the years. Jay Hancock, Kaiser Health News and Sarah Jane Tribble, Kaiser Health News Prescription drug prices […]
In our top stories this week, we have a generic drug pricing scam, Germany beating the U.S. (and not in soccer) and a growing number of primary elections focused on candidates supporting Medicare for All. In a related article, doctor burnout because of uninsured patients […]
By delaying development of generics, drugmakers can maintain their monopolies and keep prices high. Most of the drugs cost Medicare Part D more in 2016 than they did in 2012, for an average spending increase of about 60 percent more per unit. This excludes drugs […]
The story of Korlym highlights how America’s drug development system can turn an old drug into a new one that treats relatively few — but often very desperate — patients. Sarah Jane Tribble, Kaiser Health News Even though the $550 yellow pills sold as Korlym have […]
Pharmaceutical companies are using their savings from recent corporate tax cuts to buy back shares of their own stock, enriching executives and wealthy investors as prescription drug prices continue to skyrocket, says Robert Reich, former Secretary of Labor. “It’s a two part scam,” he said. […]
Americans may be warming to the idea of a national health plan, such as the Medicare-for-all idea advocated by Sen. Bernie Sanders (I-Vt.). Overall, 59 percent said they supported it, and even more, 75 percent, said they would support it if it were one option […]
